摘要
背景:为什么全球范围内引起急性神经肌肉麻痹的主要原因是自身免疫性疾病,而目前还没有一种特征明确的病因或有效的治疗方法?Guillain-Barre综合征(GBS)存在不同的临床变异,加上大量病原体可能导致感染,有时但并非总是先于该综合征的发展,给预后和治疗带来很大程度的不确定性。在后基因组时代,用于生物分子高通量分析的组学技术的发展使生物系统的描述达到了前所未有的深度。在此背景下,本文综述了后基因组学技术在GBS研究中的应用.方法:对文献数据库进行结构化检索,总结后基因组学技术在GBS研究中的应用现状。检索到的论文的质量使用标准工具进行了评估,其中34篇被包括在审查中。迄今为止,转录组学和蛋白质组学已经成为GBS研究中独特的后基因组学方法.这些研究大多是在脑脊液标本上进行的,而对其他样本如血清、雪旺细胞和人周围神经的研究则很少。结果与结论:在后基因组学时代,转录组学和蛋白质组学技术为更好地理解GBS的免疫学和病理机制以及识别潜在的生物标记物提供了可能,但这些结果仅显示出冰山一角,而后基因组学方法为GBS的研究提供了很大的潜力。通过系统生物学方法整合不同的组学数据集,可以使基于网络的分析能够描述疾病过程中所涉及的分子机制的复杂性和功能性,从而有助于发现新的生物标志物,这些标志物可用于改进诊断,预测疾病进展,提高我们对病理的理解,并作为GBS的治疗靶点。
关键词: 后基因组学方法,格林 - 巴利综合征,转录组学,蛋白质组学,系统生物学,神经退行性疾病。
Current Medicinal Chemistry
Title:The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Volume: 25 Issue: 29
关键词: 后基因组学方法,格林 - 巴利综合征,转录组学,蛋白质组学,系统生物学,神经退行性疾病。
摘要: Background: Why an autoimmune disease that is the main cause of the acute neuromuscular paralysis worldwide does not have a well-characterized cause or an effective treatment yet? The existence of different clinical variants for the Guillain-Barré syndrome (GBS) coupled with the fact that a high number of pathogens can cause an infection that sometimes, but not always, precedes the development of the syndrome, confers a high degree of uncertainty for both prognosis and treatment. In the post-genomic era, the development of omics technologies for the high-throughput analysis of biological molecules is allowing the characterization of biological systems in a degree of depth unimaginable before. In this context, this work summarizes the application of post-genomics technologies to the study of GBS.
Methods: We performed a structured search of bibliographic databases for peer-reviewed research literature to outline the state of the art with regard the application of post-genomics technologies to the study of GBS. The quality of retrieved papers was assessed using standard tools and thirty-four were included in the review. To date, transcriptomics and proteomics have been the unique post-genomics approaches applied to GBS study. Most of these studies have been performed on cerebrospinal fluid samples and only a few studies have been conducted with other samples such as serum, Schwann cells and human peripheral nerve.
Results and Conclusion: In the post-genomics era, transcriptomics and proteomics have shown the possibilities that omics technologies can offer for a better understanding of the immunological and pathological mechanisms involved in GBS and the identification of potential biomarkers, but these results have only shown the tip of the iceberg and there is still a long way to exploit the full potential that post-genomics approaches could offer to the study of the GBS. The integration of different omics datasets through a systems biology approach could allow network-based analyses to describe the complexity and functionality of the molecular mechanisms involved in the course of disease facilitating the discovery of novel biomarkers that could be used to improve the diagnosis, predict the disease progression, improve our understanding of the pathology, and serve as therapeutic targets for GBS.
Export Options
About this article
Cite this article as:
The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome, Current Medicinal Chemistry 2018; 25 (29) . https://dx.doi.org/10.2174/0929867325666180314121813
DOI https://dx.doi.org/10.2174/0929867325666180314121813 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allosteric Regulators of the Proteasome: Potential Drugs and a Novel Approach for Drug Design
Current Medicinal Chemistry Colon as Target for Drug Delivery
Current Drug Therapy Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on the Use of Biologics in Lupus
Current Pharmaceutical Biotechnology VEGFR1 Signaling Regulates IL-4-Mediated Arginase 1 Expression in Macrophages
Current Molecular Medicine The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Generation of Regulatory T Cells to Antigen Expressed in the Retina
Current Immunology Reviews (Discontinued) B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Mechanism by which Regulatory Rheumatoid Factor Prevents Experimental Autoimmune Encephalomyelitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Natural Killer T Cells and Autoimmune Disease
Current Molecular Medicine Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design